Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970. The authors have advised that there are errors in the first row of Table 5 on page 963. Cariprazine 4.5 mg column, the value “1 (0.0)” should ...
Guardado en:
Autores principales: | Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy Á, et al.
Publicado: (2021) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021) -
Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021) -
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes JM, et al.
Publicado: (2021) -
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome L
Publicado: (2018)